Veracyte Ownership
| VCYT Stock | USD 23.51 0.71 2.93% |
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 79.9 M | Current Value 80.1 M | Avarage Shares Outstanding 45.4 M | Quarterly Volatility 22.2 M |
Veracyte Stock Ownership Analysis
About 99.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.59. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Veracyte had not issued any dividends in recent years. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people. For more information please call Bonnie Anderson at 650 243 6300 or visit https://www.veracyte.com.Besides selling stocks to institutional investors, Veracyte also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Veracyte's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Veracyte's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Veracyte Quarterly Liabilities And Stockholders Equity |
|
Veracyte Insider Trades History
Less than 1% of Veracyte are currently held by insiders. Unlike Veracyte's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Veracyte's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Veracyte's insider trades
Veracyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Veracyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Veracyte backward and forwards among themselves. Veracyte's institutional investor refers to the entity that pools money to purchase Veracyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-03-31 | 1.9 M | Driehaus Capital Management Llc | 2025-03-31 | 1.4 M | Gw&k Investment Management, Llc | 2025-03-31 | 1.3 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.2 M | Bank Of America Corp | 2025-03-31 | 1.2 M | Nuveen, Llc | 2025-03-31 | 1.1 M | Goldman Sachs Group Inc | 2025-03-31 | 1 M | Northern Trust Corp | 2025-03-31 | 1 M | First Trust Advisors L.p. | 2025-03-31 | 1 M | Vanguard Group Inc | 2025-03-31 | 8.3 M | Blackrock Inc | 2025-03-31 | 7.5 M |
Veracyte Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Veracyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Veracyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Veracyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Veracyte's latest congressional trading
Congressional trading in companies like Veracyte, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Veracyte by those in governmental positions are based on the same information available to the general public.
| 2025-07-11 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
| 2020-11-05 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
| 2020-02-18 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
| 2020-01-06 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Veracyte Outstanding Bonds
Veracyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Veracyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Veracyte bonds can be classified according to their maturity, which is the date when Veracyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Veracyte Corporate Filings
F4 | 23rd of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of June 2025 Other Reports | ViewVerify | |
| 14th of May 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.